Elevated risk of adverse effects from foodborne contaminants and drugs in inflammatory bowel disease: a review.

Autor: Walraven T; Division of Toxicology, Wageningen University and Research, Wageningen, The Netherlands. tom.walraven@wur.nl., Busch M; Division of Toxicology, Wageningen University and Research, Wageningen, The Netherlands., Wang J; Division of Toxicology, Wageningen University and Research, Wageningen, The Netherlands., Donkers JM; Department of Metabolic Health Research, Netherlands Organization for Applied Scientific Research (TNO), Leiden, The Netherlands., Duijvestein M; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands., van de Steeg E; Department of Metabolic Health Research, Netherlands Organization for Applied Scientific Research (TNO), Leiden, The Netherlands., Kramer NI; Division of Toxicology, Wageningen University and Research, Wageningen, The Netherlands., Bouwmeester H; Division of Toxicology, Wageningen University and Research, Wageningen, The Netherlands.
Jazyk: angličtina
Zdroj: Archives of toxicology [Arch Toxicol] 2024 Nov; Vol. 98 (11), pp. 3519-3541. Date of Electronic Publication: 2024 Sep 09.
DOI: 10.1007/s00204-024-03844-w
Abstrakt: The global burden of Inflammatory bowel disease (IBD) has been rising over the last decades. IBD is an intestinal disorder with a complex and largely unknown etiology. The disease is characterized by a chronically inflamed gastrointestinal tract, with intermittent phases of exacerbation and remission. This compromised intestinal barrier can contribute to, enhance, or even enable the toxicity of drugs, food-borne chemicals and particulate matter. This review discusses whether the rising prevalence of IBD in our society warrants the consideration of IBD patients as a specific population group in toxicological safety assessment. Various in vivo, ex vivo and in vitro models are discussed that can simulate hallmarks of IBD and may be used to study the effects of prevalent intestinal inflammation on the hazards of these various toxicants. In conclusion, risk assessments based on healthy individuals may not sufficiently cover IBD patient safety and it is suggested to consider this susceptible subgroup of the population in future toxicological assessments.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: